Vitamin D in Cutaneous T-Cell Lymphoma

Research output: Contribution to journalReviewResearchpeer-review

Standard

Vitamin D in Cutaneous T-Cell Lymphoma. / Ødum, August Witte Feentved; Geisler, Carsten.

In: Cells, Vol. 13, No. 6, 503, 2024.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Ødum, AWF & Geisler, C 2024, 'Vitamin D in Cutaneous T-Cell Lymphoma', Cells, vol. 13, no. 6, 503. https://doi.org/10.3390/cells13060503

APA

Ødum, A. W. F., & Geisler, C. (2024). Vitamin D in Cutaneous T-Cell Lymphoma. Cells, 13(6), [503]. https://doi.org/10.3390/cells13060503

Vancouver

Ødum AWF, Geisler C. Vitamin D in Cutaneous T-Cell Lymphoma. Cells. 2024;13(6). 503. https://doi.org/10.3390/cells13060503

Author

Ødum, August Witte Feentved ; Geisler, Carsten. / Vitamin D in Cutaneous T-Cell Lymphoma. In: Cells. 2024 ; Vol. 13, No. 6.

Bibtex

@article{a38d53a17c464aa2b7b8adc2bd8e1642,
title = "Vitamin D in Cutaneous T-Cell Lymphoma",
abstract = "Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL.",
keywords = "CTCL, pathogenesis, treatment, vitamin D",
author = "{\O}dum, {August Witte Feentved} and Carsten Geisler",
note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",
year = "2024",
doi = "10.3390/cells13060503",
language = "English",
volume = "13",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI AG",
number = "6",

}

RIS

TY - JOUR

T1 - Vitamin D in Cutaneous T-Cell Lymphoma

AU - Ødum, August Witte Feentved

AU - Geisler, Carsten

N1 - Publisher Copyright: © 2024 by the authors.

PY - 2024

Y1 - 2024

N2 - Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL.

AB - Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions. Mycosis fungoides (MF)—the most common variant of CTCL—often presents with skin lesions around the abdomen and buttocks (“bathing suit” distribution), i.e., in skin areas devoid of sun-induced vitamin D. For decades, sunlight and vitamin D have been connected to CTCL. Thus, vitamin D induces apoptosis and inhibits the expression of cytokines in malignant T cells. Furthermore, CTCL patients often display vitamin D deficiency, whereas phototherapy induces vitamin D and has beneficial effects in CTCL, suggesting that light and vitamin D have beneficial/protective effects in CTCL. Inversely, vitamin D promotes T helper 2 (Th2) cell specific cytokine production, regulatory T cells, tolerogenic dendritic cells, as well as the expression of immune checkpoint molecules, all of which may have disease-promoting effects by stimulating malignant T-cell proliferation and inhibiting anticancer immunity. Studies on vitamin D treatment in CTCL patients showed conflicting results. Some studies found positive effects, others negative effects, while the largest study showed no apparent clinical effect. Taken together, vitamin D may have both pro- and anticancer effects in CTCL. The balance between the opposing effects of vitamin D in CTCL is likely influenced by treatment and may change during the disease course. Therefore, it remains to be discovered whether and how the effect of vitamin D can be tilted toward an anticancer response in CTCL.

KW - CTCL

KW - pathogenesis

KW - treatment

KW - vitamin D

U2 - 10.3390/cells13060503

DO - 10.3390/cells13060503

M3 - Review

C2 - 38534347

AN - SCOPUS:85188705459

VL - 13

JO - Cells

JF - Cells

SN - 2073-4409

IS - 6

M1 - 503

ER -

ID: 388046679